Last reviewed · How we verify
sulopenem etzadroxil and probenecid
At a glance
| Generic name | sulopenem etzadroxil and probenecid |
|---|---|
| Also known as | Orlynvah |
| Sponsor | Iterum Therapeutics, International Limited |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Diarrhea
- Nausea
- Vulvovaginal mycotic infection
- Headache
- Vomiting
Serious adverse events
- Serious adverse reactions (unspecified)
Key clinical trials
- Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents (PHASE1)
- Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women (PHASE3)
- Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: